A Chinese biotechnology firm has secured a significant licensing agreement worth potentially over $1 billion for an experimental autoimmune disease treatment. The partnership with Belgium-based UCB includes $60 million upfront with additional milestone payments.
A Chinese biotechnology company announced Wednesday that it has struck a major licensing deal with Belgian pharmaceutical giant UCB for an experimental treatment targeting autoimmune conditions, with the agreement potentially worth more than $1.1 billion.
Antengene Corporation revealed that UCB will pay $60 million immediately and could provide additional payments exceeding $1.1 billion if specific development goals are achieved for the experimental drug ATG-201.
In a company statement posted online, Antengene highlighted that the partnership demonstrates the “unique” capabilities of its drug development platform. Following the announcement, the company’s Hong Kong stock shares climbed approximately 6% during Wednesday morning trading.
The experimental medication ATG-201 is designed to treat autoimmune conditions related to B-cells. Antengene intends to file for clinical trial approval in both Australia and China during the opening quarter of 2026, and once initial phase I testing concludes, UCB will assume responsibility for continued development.
The licensing arrangement grants UCB global rights to develop, produce, and market ATG-201, along with access to related manufacturing processes. Beyond the initial $60 million payment, Antengene stands to receive additional compensation tied to “certain conditions,” development achievements, and commercial success markers, plus ongoing royalty payments based on future sales revenue.
Middle East Conflict Disrupts Air Travel Worldwide, Strands Thousands
Rhode Island Attorney General Set to Release Major Clergy Abuse Investigation Report
Texas Primary: State Rep. Steve Toth Defeats Incumbent Dan Crenshaw
Musk Set to Testify in Trial Over Twitter Stock Price Manipulation Claims